ArriVent BioPharma, Inc. (AVBP) is a pioneering biopharmaceutical company dedicated to developing innovative therapies for significant unmet medical needs in oncology and autoimmune diseases. With a strong pipeline supported by proprietary technologies and a rigorous scientific approach, the company aims to improve patient outcomes markedly. By focusing on high-growth areas within the biopharma industry, ArriVent presents a compelling investment opportunity for institutional investors interested in transformative healthcare solutions poised for substantial market influence.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -55.20% |
| Return on Assets | -34.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.15 |
| Price-to-Book | 4.99 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $46.57M |
| Float | $29.78M |
| % Insiders | 1.63% |
| % Institutions | 95.87% |
Volatility is currently contracting
NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent Company progress.
Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is how ArriVent BioPharma, Inc. (AVBP) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
